- Home
- Results news
- Nureca
- Q2 FY27 results
Nureca Q2 FY27 results: net profit down 8.8% to ₹4.05 crore, revenue down 18.6%
Nureca Limited reported consolidated revenue of ₹58.53 crore in Q2 FY27, up 45.1% from Q1 FY27 but down 18.6% from Q2 FY26. EBITDA rose to ₹5.23 crore and the margin widened to 8.9%, while net profit was ₹4.05 crore and basic EPS was ₹4.25.
Key points
- Consolidated revenue was ₹58.53 crore in Q2 FY27, up ₹18.19 crore or 45.1% from Q1 FY27 and down ₹13.39 crore or 18.6% from Q2 FY26.
- EBITDA was ₹5.23 crore, up ₹1.81 crore or 52.9% from Q1 FY27 and ₹2.52 crore or 93.0% from Q2 FY26; EBITDA margin was 8.9%.
- Net profit was ₹4.05 crore, up ₹0.98 crore or 31.9% from Q1 FY27 and down ₹0.39 crore or 8.8% from Q2 FY26; basic EPS was ₹4.25.
- Total expenses were ₹54.36 crore, down ₹16.62 crore or 23.4% from Q2 FY26, while other income fell ₹3.54 crore or 72.4%.
- The same-day press release said revenue growth was broad-based across e-commerce, quick-commerce and offline distribution, and that working capital increased ahead of the festive and winter season.
How did Nureca perform in Q2 FY27?
Nureca reported consolidated revenue from operations of ₹58.53 crore for Q2 FY27, compared with ₹40.34 crore in Q1 FY27 and ₹71.92 crore in Q2 FY26. Total income was ₹59.88 crore, against ₹42.16 crore in the previous quarter and ₹76.81 crore in the year-ago quarter. The standalone revenue for the quarter was ₹58.6 crore, up 54.9% from ₹37.74 crore in the press release’s year-on-year comparison.
EBITDA was ₹5.23 crore, up from ₹3.42 crore in Q1 FY27 and ₹2.71 crore in Q2 FY26. The EBITDA margin was 8.9%, compared with 8.5% in Q1 FY27 and 3.8% in Q2 FY26. Profit before tax was ₹5.52 crore, against ₹4.43 crore in Q1 FY27 and ₹5.83 crore in Q2 FY26.
Nureca reported a net profit of ₹4.05 crore for Q2 FY27, compared with ₹3.07 crore in Q1 FY27 and ₹4.44 crore in Q2 FY26. Basic EPS was ₹4.25, against ₹3.21 in Q1 FY27 and ₹4.44 in Q2 FY26. On the standalone basis, revenue was ₹58.6 crore and profit after tax was ₹3.62 crore, compared with ₹3.14 crore in the year-ago period.
| ₹ crore | Q2 FY27 | Q1 FY27 | Q2 FY26 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 58.53 | 40.34 | 71.92 | −18.6% | +45.1% |
| Other income | 1.35 | 1.82 | 4.89 | −72.4% | −25.8% |
| Total expenses | 54.36 | 37.73 | 70.98 | −23.4% | +44.1% |
| EBITDA | 5.23 | 3.42 | 2.71 | +93.0% | +52.9% |
| EBITDA margin | 8.9% | 8.5% | 3.8% | +5.1 pp | +0.4 pp |
| Profit before tax | 5.52 | 4.43 | 5.83 | −5.3% | +24.6% |
| Tax | 1.47 | 1.36 | 1.39 | +5.8% | +8.1% |
| Net profit | 4.05 | 3.07 | 4.44 | −8.8% | +31.9% |
| EPS (₹) | 4.25 | 3.21 | 4.44 | −4.3% | +32.4% |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in Nureca's costs and profit?
Against Q2 FY26, total expenses fell ₹16.62 crore or 23.4% to ₹54.36 crore. Cost of materials consumed declined ₹3.71 crore or 37.7% to ₹6.14 crore, employee benefits expense fell ₹4.51 crore or 52.3% to ₹4.11 crore, finance costs declined ₹0.45 crore or 63.4% to ₹0.26 crore, and depreciation fell ₹0.26 crore or 24.3% to ₹0.81 crore. Other expenses decreased ₹4.15 crore or 28.4% to ₹10.45 crore. There was no exceptional item in either period.
Other income declined ₹3.54 crore or 72.4% to ₹1.35 crore from ₹4.89 crore, while tax expense increased ₹0.08 crore or 5.8% to ₹1.47 crore. Profit before tax therefore fell ₹0.31 crore or 5.3% to ₹5.52 crore, and net profit declined ₹0.39 crore or 8.8% to ₹4.05 crore. The company said revenue growth was broad-based across its e-commerce, quick-commerce and offline distribution channels.
Compared with Q1 FY27, total expenses rose ₹16.63 crore or 44.1% to ₹54.36 crore. Cost of materials consumed increased ₹1.18 crore or 23.8% to ₹6.14 crore and other expenses rose ₹2.65 crore or 34.0% to ₹10.45 crore, while employee benefits expense fell ₹0.32 crore or 7.2% to ₹4.11 crore. Other income was down ₹0.47 crore or 25.8% at ₹1.35 crore, and tax expense rose ₹0.11 crore or 8.1% to ₹1.47 crore.
| ₹ crore | Q2 FY27 | Q2 FY26 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 6.14 | 9.85 | −3.71 | −37.7% |
| Employee cost | 4.11 | 8.62 | −4.51 | −52.3% |
| Finance costs | 0.26 | 0.71 | −0.45 | −63.4% |
| Depreciation | 0.81 | 1.07 | −0.26 | −24.3% |
| Other expenses | 10.45 | 14.60 | −4.15 | −28.4% |
| Total expenses | 54.36 | 70.98 | −16.62 | −23.4% |
| Other income | 1.35 | 4.89 | −3.54 | −72.4% |
| Tax | 1.47 | 1.39 | +0.08 | +5.8% |
Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
At 30 September 2026, Nureca reported total assets of ₹231.28 crore and total equity of ₹187.88 crore, compared with ₹196.16 crore and ₹180.76 crore at 31 March 2026. Borrowings were ₹1.77 crore, against ₹0.72 crore at the previous balance sheet date, and cash and cash equivalents were ₹1.11 crore, compared with ₹1.46 crore. Inventories were ₹62.99 crore, trade receivables were ₹27.11 crore, and trade payables were ₹30.21 crore.
Cash flow from operating activities was negative ₹12.54 crore in H1 FY27, compared with ₹4.45 crore in H1 FY26. Investing cash flow was ₹12.45 crore against negative ₹6.72 crore, while financing cash flow was negative ₹0.26 crore against ₹0.22 crore. Capital expenditure was ₹21.4 crore in H1 FY27, compared with ₹5.45 crore in H1 FY26.
| ₹ crore | As of 30 September 2026 | As of 31 March 2026 |
|---|---|---|
| Total assets | 231.28 | 196.16 |
| Total equity | 187.88 | 180.76 |
| Borrowings | 1.77 | 0.72 |
| Cash and equivalents | 1.11 | 1.46 |
| Inventories | 62.99 | 47.51 |
| Trade receivables | 27.11 | 7.75 |
Source: Company's results filing (XBRL).
| ₹ crore | H1 FY27 | H1 FY26 |
|---|---|---|
| Cash from operations | −12.54 | 4.45 |
| Cash from investing | 12.45 | −6.72 |
| Cash from financing | −0.26 | 0.22 |
| Capital expenditure | 21.40 | 5.45 |
Source: Company's results filing (XBRL).
How has Nureca done over the last 8 quarters?
Revenue increased from ₹34.18 crore in Q1 FY26 to ₹71.92 crore in Q2 FY26, before falling to ₹39.64 crore in Q3 FY26 and ₹35.41 crore in Q4 FY26. It then rose to ₹40.34 crore in Q1 FY27 and ₹58.53 crore in Q2 FY27. The highest quarterly revenue in the period was ₹71.92 crore in Q2 FY26, while the lowest was ₹26.46 crore in Q3 FY25.
Profit after tax was ₹4.44 crore in Q2 FY26 and fell to negative ₹6.09 crore in Q4 FY26, before recovering to ₹3.07 crore in Q1 FY27 and ₹4.05 crore in Q2 FY27. EBITDA margin moved from negative 16.3% in Q4 FY26 to 8.5% in Q1 FY27 and 8.9% in Q2 FY27. The current quarter therefore showed higher revenue, profit and margin than the immediately preceding quarter, but revenue and profit remained below Q2 FY26.
What else did the company announce?
The board approved the unaudited standalone and consolidated financial results, cash flow statement and statement of assets and liabilities for the quarter and half year ended 30 September 2026, along with limited review reports. The meeting began at 12:30 PM and concluded at 13:25 PM on 21 October 2026. The same-day press release described Q2 FY27 revenue of ₹58.53 crore as the company’s highest quarterly revenue in 20 quarters.
The same-day filing did not announce a dividend, fund raise or appointment. The press release said Nureca was expanding its manufacturing base in Punjab for medical devices, healthcare consumables and hygiene products, and that its products include home diagnostics, fitness and body metrics, massage therapy, orthopaedic support, mother and baby care, and home wellness.
How did Nureca shares react?
After the filing appeared, the stock moved up 2.3% within five minutes, 2.7% within 15 minutes and 3.0% within 30 minutes. It closed the reaction day up 3.7% from the pre-results close. By the next day’s close, it was up 3.5% from that close, while by the five-day close it was down 5.1%.
| After the filing | Stock | Medical Equipment & Supplies median |
|---|---|---|
| 5 minutes | +2.3% | |
| 15 minutes | +2.7% | |
| 30 minutes | +3.0% | |
| Reaction day | +3.7% | −3.0% |
| Next day | +3.5% | −4.7% |
| 5 days | −5.1% | −3.5% |
Minutes are measured from the price when the filing appeared; days from the previous close. Source: MarketPing price-reaction measurement.
| Results filed on | Stock on the reaction day |
|---|---|
| 21 July 2026 | +4.6% |
| 29 May 2026 | −14.8% |
| 17 January 2026 | +5.0% |
| 16 October 2025 | +16.6% |
| 15 July 2025 | −8.7% |
| 5 May 2025 | +2.0% |
| 24 January 2025 | −5.0% |
| 24 October 2024 | −2.8% |
Source: MarketPing price-reaction measurement.
Quick answers
What was Nureca's revenue in Q2 FY27?
Revenue from operations was ₹58.53 crore, down 18.6% from ₹71.92 crore in Q2 FY26 (consolidated).
Did Nureca make a profit in Q2 FY27?
Yes. Net profit was ₹4.05 crore, against a net profit of ₹4.44 crore in Q2 FY26.
What was Nureca's EPS in Q2 FY27?
Basic earnings per share were ₹4.25, against ₹4.44 in Q2 FY26.
How did Nureca shares react to the Q2 FY27 results?
On the reaction day the stock moved +3.7% from the previous close; the median Medical Equipment & Supplies stock moved −3.0%.
When did Nureca announce its Q2 FY27 results?
On 21 October 2026, in a filing to the BSE.
Sources
- Board Meeting Intimation for Considering And Approving, Inter-Alia, The Un-Audited Financial Results (Standalone And Consolidated) Of The Company For Quarter And Half Year Ended September 30, 2026. (BSE, 14 October 2026) · PDF
- Board Meeting Outcome for Un-Audited Financial Results For The Quarter And Half Year Ended 30Th September,2026 (BSE, 21 October 2026) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.